story of the week
AACR 2020: Addition of Durvalumab and Olaparib to Paclitaxel Increases Response Rates in Breast Cancer
Benefits were seen in multiple HER2 and hormone receptor-based biomarker subgroups
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles: